Compare Dollar General Corp. (DG) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dollar General Corp. vs Eli Lilly And Co — how do they compare? Dollar General Corp. trades at $119.28 (market cap $26.49B), while Eli Lilly And Co trades at $1,216 (market cap $1.08T). The key difference: Eli Lilly And Co is far larger — about 40.8× Dollar General Corp.'s market cap, and Dollar General Corp. pays the higher dividend (1.97%). Which is the better fit depends on your goals.
| DG | LLY | |
|---|---|---|
Market Cap | $26.49B | $1.08T |
Sector | Consumer Staples | Health |
52-Week High | $156.26 | $1.24K |
52-Week Low | $95.94 | $639.43 |
Enterprise Value | $40.93B | $1.13T |
Dividend Yield | 1.97% | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dollar General (DG) trades at $119.40, down 2.44% on the day, with a bullish technical signal despite recent weakness. The stock shows strong fundamentals with a P/E of 16.98 and P/S of 0.62, while consistently beating earnings expectations in recent quarters. Revenue growth continues with $40.61B in 2025, though profit margins have compressed from 7.01% in 2022 to 2.77% in 2025. Analyst consensus remains positive with 52% buy ratings and a $128.45 price target, representing 7.6% upside potential.
DG presents a compelling value opportunity with reasonable valuation metrics and consistent earnings beats, though margin compression and competitive pressures pose risks. The stock's current price near support levels combined with positive analyst sentiment suggests potential for recovery, but investors should monitor margin trends and competitive dynamics in the discount retail sector.
Eli Lilly (LLY) trades at $1,221.21, down 0.84% today, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows technical strength with bullish moving averages and support at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 48% revenue growth in Q2 2026. Recent news highlights the company's aggressive protection of its obesity drug pipeline against black market sales.
LLY presents a compelling growth story with dominant market positioning in weight-loss drugs and strong analyst support (73% buy ratings). Key risks include regulatory scrutiny and competitive pressures, but the company's raised guidance and pipeline advancements support continued upside toward the $1,380 consensus target.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dollar General Corp.
A leading American discount retailer, Dollar General operates over 18,000 stores in 47 states, selling branded and private-label products across a wide variety of categories. In fiscal 2021, 77% of net sales came from consumables (including paper and cleaning products, packaged and perishable food, tobacco, and health and beauty items), 12% from seasonal merchandise (such as toys, greeting cards, decorations, and gardening supplies), 7% from home products (for example, kitchen supplies, small appliances, and cookware), and 4% from basic apparel. Stores average roughly 7,400 square feet, and about 75% of Dollar General locations are in towns of 20,000 or fewer people. The firm emphasizes value, with most of its items sold at everyday low prices of $5 or less.
Read more on DG →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
